Oxaliplatin induced-neuropathy in digestive tumors

Sereno, María; Gutiérrez-Gutiérrez, Gerardo; Gómez-Raposo, César; López-Gómez, Miriam; Merino-Salvador, Maria; Tébar, Francisco Zambrana; Rodríguez‐Antona, Cristina; Casado, Enrique

doi:10.1016/j.critrevonc.2013.08.009

Cited by 42 publications

(48 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its installation is acute and of rapidly progressing intensity, lasts for a variable period and tends to decrease in intensity some days later. Chemotherapy-INP pain affects more than 90% of patients under treatment 17,18 , is in general triggered by cold, affecting distal limbs, mouth, jaw pain when biting and mouth paresthesia 19,20 and may be simultaneous with pharyngolaryngeal dysesthesia 21 . There might also be muscle spasms, fasciculations and cramps 20 .…”

Section: Clinical Presentationmentioning

confidence: 99%

Post-chemotherapy neuropathy

Caponero¹,

Montarroyos²,

Tahamtani³

2016

Revista Dor

View full text Add to dashboard Cite

Section: Clinical Presentationmentioning

confidence: 99%

Post-chemotherapy neuropathy

Caponero¹,

Montarroyos²,

Tahamtani³

2016

Revista Dor

View full text Add to dashboard Cite

“…Numerous methods to prevent or eliminate neurotoxicity have been tested without success [11,12]. Guidelines from ASCO state that there are no existing agents to prevent chemotherapy-induced neurotoxicity.…”

Section: Introductionmentioning

confidence: 99%

The trajectory of neurotoxic side effects’ impact on daily life: a qualitative study

Drott

Starkhammar

Kjellgren

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

Purpose To explore the experiences of oxaliplatin-induced neurotoxic side effects among patients with colorectal cancer (CRC), and how these side effects influenced their daily lives over time.Methods To assess neurotoxic side effects, ten patients were repeatedly interviewed. The patients were recruited from two hospitals in south of Sweden, had stage II-III CRC, and had been treated with adjuvant oxaliplatin postoperatively, from November 2013 to October 2015. They had received FOLFOX and XELOX, with a mean total dose of 791 mg oxaliplatin. After completed chemotherapy, at 3, 6 and 12 months into the post-treatment phase, 25 interviews were conducted and thematic analysis was used according to Braun and Clarke.Results Oxaliplatin-induced neurotoxicity affects patients in several ways in the long term. Four themes were identified: Expectation of cure, Dubiety, Normalization and Learn to live with neurotoxity. The findings of this study describe the trajectory of neurotoxicity and its impact on these patients' life situation. The findings confirmed that neurotoxicity is multi-faceted and that the experience of it changes over time. ConclusionThe desire to survive stimulates adaptations and strategies to manage daily life, and patients learn to live with the neurotoxic side effects. This study provides evidence that these patients need individual attention and support during the trajectory of neurotoxic side effects. Current care provision is inadequate due to lack of knowledge of the ways in which neurotoxicity impacts the patient's daily life. This study provides insights that could be used to develop more person-centered care.

show abstract

“…Chronically, OX produces defects that are predominantly sensory owing to its access to and accumulation in dorsal root ganglia, where this platinum-based compound causes DNA damage and cell death or secondary peripheral axonopathy of primary sensory neurons (Boulikas et al 2007). Chemotherapy-induced peripheral neuropathy (CIPN) with OX has been demonstrated for peripheral axons by clinical electrophysiology [reduction to roughly half normal amplitude of evoked sensory nerve action potentials (SNAPs); Lehky et al 2004; Park et al 2011; Bennett et al 2012] and/or histology (reduced nerve innervation in epidermal biopsies; Koskinen et al 2011; Sereno et al 2014). CIPN is the common diagnosis and the dose-limiting side-effect used to explain the movement disability caused by OX, including postural instability, clumsiness, and difficulties with driving and walking, symptoms inferred to reflect deficits in proprioception (Hile et al 2010; Bennett et al 2012; Tofthagen et al 2012).…”

Section: Main Bodymentioning

confidence: 99%

Complex impairment of IA muscle proprioceptors following traumatic or neurotoxic injury

et al. 2015

View full text Add to dashboard Cite

The health of primary sensory afferents supplying muscle has to be a first consideration in assessing deficits in proprioception and related motor functions. Here we discuss the role of a particular proprioceptor, the IA muscle spindle proprioceptor in causing movement disorders in response to either regeneration of a sectioned peripheral nerve or damage from neurotoxic chemotherapy. For each condition, there is a single preferred and widely repeated explanation for disability of movements associated with proprioceptive function. We present a mix of published and preliminary findings from our laboratory, largely from in vivo electrophysiological study of treated rats to demonstrate newly discovered IA afferent defects that seem likely to make important contributions to movement disorders. First, we argue that reconnection of regenerated IA afferents with inappropriate targets, although often repeated as the reason for lost stretch–reflex contraction, is not a complete explanation. We present evidence that despite successful recovery of stretch-evoked sensory signaling, peripherally regenerated IA afferents retract synapses made with motoneurons in the spinal cord. Second, we point to evidence that movement disability suffered by human subjects months after discontinuation of oxaliplatin (OX) chemotherapy for some is not accompanied by peripheral neuropathy, which is the acknowledged primary cause of disability. Our studies of OX-treated rats suggest a novel additional explanation in showing the loss of sustained repetitive firing of IA afferents during static muscle stretch. Newly extended investigation reproduces this effect in normal rats with drugs that block Na+ channels apparently involved in encoding static IA afferent firing. Overall, these findings highlight multiplicity in IA afferent deficits that must be taken into account in understanding proprioceptive disability, and that present new avenues and possible advantages for developing effective treatment. Extending the study of IA afferent deficits yielded the additional benefit of elucidating normal processes in IA afferent mechanosensory function.

show abstract

Oxaliplatin induced-neuropathy in digestive tumors

Cited by 42 publications

References 72 publications

Post-chemotherapy neuropathy

Post-chemotherapy neuropathy

The trajectory of neurotoxic side effects’ impact on daily life: a qualitative study

Complex impairment of IA muscle proprioceptors following traumatic or neurotoxic injury

Contact Info

Product

Resources

About